Recent Research in LNCaP Cells Inhibition of BCL-2 by Antisense Oligonucleotides Results in Compensatory Changes Involving Apoptosis,Transcription and Immunoregulation
Antisense oligonucleotides (oligos) have been evaluated for treating prostate cancer in both in vivo and in vitro models. This study evaluates the growth inhibition of in vitro propagating LNCaP cells employing mono- and bi-specific oligos directed against BCL-2 and employing RT-PCR, the expression of five apoptosis regulatory proteins (BCL-2, bax, caspase-3, clusterin, AKT-1), a tumor…
Read more